CTOs on the Move


 
At Draper` we believe exciting things happen when new capabilities are imagined and created. Whether formulating a concept and developing each component to achieve a field-ready prototype or combining existing technologies in new ways` Draper engineers apply multidisciplinary approaches that deliver new capabilities to customers. As a not-for-profit research and development company` Draper focuses on the design` development and deployment of advanced technological solutions for the world’s most challenging and important problems. We provide engineering services directly to government` industry` and academia; work on teams as prime contractor or subcontractor; and participate as a collaborator in consortia. We provide unbiased ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.draper.com
  • 555 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.258.1000

Executives

Name Title Contact Details
Kevin Burns
Chief Information Security Officer Profile

Similar Companies

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioVex Inc

BioVex Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spinemark

Spinemark is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Protein Sciences Corporation

Protein Sciences Corporation is a Meriden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

We employ our Ligand Activated Therapy (LAT) platform technology to create new molecular entity (NME) prodrugs in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. Our most advanced product candidate, KP201/APAP, consists of KP201, our prodrug of hydrocodone, formulated in combination with acetaminophen (APAP). We are developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute moderate to moderately severe pain. KP201/APAP was designed with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. We designed KP201/APAP to deter tampering and abuse by selecting a molecular structure that prevents the release of the opioid upon crushing, physical manipulation and other commonly employed extraction techniques. We believe this approach to abuse-deterrence at the molecular level may be more effective than many formulation-based abuse-deterrence technologies, which combine the opioid drug with another drug or use an abuse-deterrent capsule or physical matrix. In addition to KP201/APAP, KemPharm is building a pipeline of NME prodrug product candidates that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.